Acorda Therapeutics, Inc. (ACOR)
| Previous Close | 0.6610 |
| Open | 0.7500 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.6610 - 0.6610 |
| 52 Week Range | 0.2500 - 24.1960 |
| Volume | |
| Avg. Volume | 137,267 |
| Market Cap | 821,028 |
| Beta (5Y Monthly) | 1.46 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Bloomberg
Riskiest Junk Bonds Shunned in Europe on Rising Risk of Default
(Bloomberg) -- The junkiest corporate debt is becoming increasingly hazardous for investors amid mounting signs that a default cycle is picking up steam. Most Read from BloombergTrumpism Is Emptying ChurchesRBC Fires CFO Ahn After Probe Into Personal RelationshipThe Odds of $100 Oil Are Rising as Supply Shocks Convulse the MarketSaudis Scale Back Ambition for $1.5 Trillion Desert Project NeomIsrael Backs Out of Khan Younis to Prepare ‘Future Operations’The holding company of Thames Water Ltd. th
- Simply Wall St.
Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) Shares Bounce 53% But Its Business Still Trails The Industry
Acorda Therapeutics, Inc. ( NASDAQ:ACOR ) shareholders are no doubt pleased to see that the share price has bounced 53...
- Insider Monkey
Acorda Therapeutics, Inc. (NASDAQ:ACOR) Q3 2023 Earnings Call Transcript
Acorda Therapeutics, Inc. (NASDAQ:ACOR) Q3 2023 Earnings Call Transcript November 13, 2023 Operator: Welcome to Acorda Therapeutics Third Quarter 2023 Financial and Business Update. At this time, all participants are in a listen-only mode. There will be a question-and-answer session to follow. Please be advised that this call is being recorded at the company’s request. […]
